Vaccine Evidence

Vaccination is the best way to prevent rotavirus disease. Rotavirus disease cannot be treated with antibiotics or other drugs, and most children are at risk of infection regardless of hygiene practices or access to clean water.

Today, two vaccines are available on the global market, several other vaccines have been licensed for national use, and promising new products are in development.

Available Rotavirus Vaccine Products

Two orally-administered, live attenuated rotavirus vaccines are currently available globally and several new products are on the horizon.

Learn More

Vaccine Health Impact

Studies show the greatest benefit of rotavirus vaccination is in low-income countries that have introduced.

Learn More

Vaccine Economic Impact

National rotavirus vaccination programs can be highly cost-effective and reduce healthcare costs due to rotavirus-related illness.

Learn More

Indirect Benefits of Rotavirus Vaccination

Countries have observed significant reductions in rotavirus hospital admissions among vaccinated and unvaccinated kids.

Learn More

Vaccines and Cross-Protection Across Strains

Available vaccines protect against a variety of circulating strains, including those not in the vaccines.

Learn More

Safety Records

WHO asserts that the benefits of rotavirus vaccines outweigh the small risk of side effects.

Learn More

Billion Dollars Saved in United States from 4 years of routine rotavirus vaccine use


Number of rotavirus-associated diarrhea cases that could be averted by vaccine in Iran between 2014-2023


Number of rotavirus vaccine products available internationally, nationally or in advanced testing


The ROTA Council was created in collaboration with an advisory group of 24 child health leaders from around the world. We promote the use of rotavirus vaccines as part of a comprehensive approach to addressing diarrheal disease.

logo-ivac logo-jhu
  • Stay up to date with the Rotavirus Organization of Technical Allies (ROTA)
    Sign up for the latest updates on rotavirus immunization-related science, policy, and access from the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health.
  • This field is for validation purposes and should be left unchanged.
Subscribe to our newsletter